With over 250 million people living with chronic hepatitis B, the prospect of a "functional cure" has long been a distant goal. Now, with recent pivotal study results for a new therapy, that goal appears closer than ever. We sit down with Faisal Zain, a leading expert in medical
A foundational pillar of American public health, the universal childhood immunization schedule, has been abruptly dismantled, igniting a fierce debate over the safety of the nation's children and the integrity of the institutions designed to protect them. This decision has created an
A New Contender Enters the Ring: Ascletis Gains Key FDA Nod for Oral Diabetes Drug Ascletis Pharma has secured a critical milestone in the competitive metabolic disease landscape, receiving Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This approval
A Paradox in the Market: When Good News Turns Bad In the high-stakes world of biopharmaceutical development, positive clinical trial results are typically a cause for celebration, often sending a company's stock soaring. Zenas Biopharma, however, recently experienced the exact opposite.
For decades, the journey to bring a new drug to market has been a marathon of immense cost and crushing uncertainty, with countless promising therapies failing long before they could reach the patients who needed them. This grueling process, often stretching over a decade and consuming billions of
The price of a single year of life has become a central and contentious calculation in modern medicine, a debate perfectly encapsulated by the arrival of targeted cancer therapies. As scientific breakthroughs deliver treatments with unprecedented efficacy, healthcare systems worldwide grapple with
